Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

NCT01092182 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

194

Enrollment

NIH

Sponsor class

Conditions

Burkitt Lymphoma
Diffuse Large B-cell Lymphoma, c-MYC Positive
Plasmablastic Lymphoma

Interventions

DRUG: EPOCH-R
DRUG: EPOCH-RR

Sponsor

National Cancer Institute (NCI)